Fig. 1.

Study design. All tumor samples were analyzed for a range of cancer-related genes such that the clinical response could be correlated with the genetic aberration. BRCA wild type was defined as no evidence of deleterious or suspected deleterious mutation in the BRCA1 or BRCA2 genes. BRCA1 and/or BRCA2 variants classified as a ‘variant of uncertain clinical significance’ or ‘variant of unknown significance,’ as well as ‘variant, favors polymorphism’ or ‘benign polymorphism,’ were considered to be BRCA wild type. Biomarker-positive TNBC and SCLC cohorts were defined as having amplifications in CCNE1, MYC, MYCL1, or MYCN. Biomarker-negative TNBC and SCLC cohorts were defined as the absence of the qualifying amplifications for TNBC or SCLC specified above. bid twice a day, BRCAm breast cancer gene 1/2 mutation, BRCAwt breast cancer gene 1/2 wild type, CCNE1 cyclin E1, n number of patients, PARPi poly(ADP-ribose) polymerase inhibitor, SCLC small-cell lung cancer, TNBC triple-negative breast cancer